{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=107",
    "query": {
      "intervention": "Safety Control",
      "page": 107
    },
    "page_size": 10
  },
  "pagination": {
    "page": 107,
    "page_size": 10,
    "total_count": 14150,
    "total_pages": 1415,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=108&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Safety+Control&page=106&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T02:48:15.533Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05085197",
      "title": "The Safety and Tolerability of STSA-1005 Following Intravenous Infusion in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "STSA-1005 injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Staidson Biopharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2021-10-27",
      "completion_date": "2022-04-05",
      "has_results": false,
      "last_update_posted_date": "2022-04-18",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05085197"
    },
    {
      "nct_id": "NCT07435610",
      "title": "Acupuncture Therapy for Pediatric Disorders of Gut-Brain Interaction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Disorders of Gut-brain Interaction"
      ],
      "interventions": [
        {
          "name": "Active Therapeutic acupuncture intervention",
          "type": "OTHER"
        },
        {
          "name": "Sham therapeutic acupuncture treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Orange County",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 96,
      "start_date": "2026-01-08",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07435610"
    },
    {
      "nct_id": "NCT01781013",
      "title": "Diabetes-Depression Care-management Adoption Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression",
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Technology-supported care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1485,
      "start_date": "2010-06",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-12-05",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 8,
      "location_summary": "El Monte, California • Lancaster, California • Long Beach, California + 4 more",
      "locations": [
        {
          "city": "El Monte",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01781013"
    },
    {
      "nct_id": "NCT00199420",
      "title": "A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Istradefylline (KW-6002)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2004-07",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 2,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00199420"
    },
    {
      "nct_id": "NCT00104520",
      "title": "Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI 75 mg two times a day (BID)/three times a day (TID)",
          "type": "DRUG"
        },
        {
          "name": "Placebo two times a day (BID)/three times a day (TID)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2005-02",
      "completion_date": "2006-09",
      "has_results": true,
      "last_update_posted_date": "2011-03-11",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 56,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104520"
    },
    {
      "nct_id": "NCT03293524",
      "title": "Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leber Hereditary Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "GS010",
          "type": "GENETIC"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "GenSight Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2018-03-12",
      "completion_date": "2024-07-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 7,
      "location_summary": "Pasadena, California • Aurora, Colorado • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03293524"
    },
    {
      "nct_id": "NCT01473524",
      "title": "Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid (OCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 217,
      "start_date": "2012-01",
      "completion_date": "2018-12-17",
      "has_results": true,
      "last_update_posted_date": "2021-05-06",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 15,
      "location_summary": "Sacramento, California • San Diego, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01473524"
    },
    {
      "nct_id": "NCT07400952",
      "title": "Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Keratoconus"
      ],
      "interventions": [
        {
          "name": "GLK-221 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaukos Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2025-12-23",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 1,
      "location_summary": "Westerville, Ohio",
      "locations": [
        {
          "city": "Westerville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07400952"
    },
    {
      "nct_id": "NCT01603147",
      "title": "Safety Study of Ch-mAb7F9 for Methamphetamine Abuse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Methamphetamine Abuse"
      ],
      "interventions": [
        {
          "name": "normal saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ch-mAb7f9",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "InterveXion Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2012-04",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2014-05-13",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603147"
    },
    {
      "nct_id": "NCT01829048",
      "title": "A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "PF-02545920",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2013-03-06",
      "completion_date": "2013-10-17",
      "has_results": true,
      "last_update_posted_date": "2018-08-20",
      "last_synced_at": "2026-11-12T02:48:15.533Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01829048"
    }
  ]
}